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Abstract
Objective Our objective was to compare the cost effec-
tiveness of stapled haemorrhoidopexy (SH) and traditional
haemorrhoidectomy (TH) in the treatment of grade II–IV
haemorrhoidal disease from the perspective of the UK
national health service.
Methods An economic evaluation was conducted along-
side an open, two-arm, parallel-group, pragmatic, multi-
centre, randomised controlled trial conducted in several
hospitals in the UK. Patients were randomised into either
SH or TH surgery between January 2011 and August 2014
and were followed up for 24 months. Intervention and
subsequent resource use data were collected using case
review forms and questionnaires. Benefits were collected
using the EQ-5D-3L (EuroQoL—five dimensions—three
levels) instrument. The primary economic outcome was
incremental cost measured in pounds (£), year 2016 values,
relative to the incremental benefit, which was estimated
using quality-adjusted life-years (QALYs). Cost and ben-
efits accrued in the second year were discounted at 3.5%.
The base-case analysis was based on imputed data.
Uncertainty was explored using univariate sensitivity
analyses.
Results Participants (n = 777) were randomised to SH
(n = 389) or TH (n = 388). The mean cost of SH was
£337 (95% confidence interval [CI] 251–423) higher than
that of TH and the mean QALYs were -0.070 (95% CI -
0.127 to -0.011) lower than for TH. The base-case cost-
utility analysis indicated that SH has zero probability of
being cost effective at both the £20,000 and the £30,000
threshold. Results from the sensitivity analyses were sim-
ilar to those from the base-case analysis.
Conclusions The evidence suggests that, on average, the
total mean costs over the 24-month follow-up period
were significantly higher for the SH arm than for the TH
arm. The QALYs were also, on average, significantly
lower for the SH arm. These results were supported by
the sensitivity analyses. Therefore, in terms of cost
effectiveness, TH is a superior surgical treatment for the
management of grade II–IV haemorrhoids when com-
pared with SH.
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Key Points for Decision Makers
Previous economic studies of traditional excisional
surgery and stapled haemorrhoidopexy were based
on limited quality-of-life data and suggested a
shorter operation time for stapled haemorrhoidopexy
than for traditional excisional surgery.
The results of this study show that traditional
excisional surgery costs less and is associated with
higher quality of life than stapled haemorrhoidopexy.
Given the current financial status of the UK national
health service, commissioners of healthcare may
consider being more prescriptive about procedures
being offered for the surgical treatment of
haemorrhoids.
1 Introduction
Haemorrhoids occur when the tissues of the distal rectum
and anal canal prolapse in the canal because of laxity of the
surrounding connective tissues and engorgement of the
blood vessel. Symptoms from haemorrhoids include
bleeding, pain, prolapse and peri-anal itch, all of which are
common within the general population [1]. The widely
adopted Goligher system [2] for grading haemorrhoids
based on their appearance and degree of prolapse was used:
• Grade I: The anal cushions bleed but do not prolapse.
• Grade II: The anal cushions prolapse through the anus
on straining but reduce spontaneously.
• Grade III: The anal cushions prolapse through the anus
on straining or exertion and require manual replace-
ment into the anal canal.
• Grade IV: The prolapse stays out at all times and is
irreducible.
The initial management of haemorrhoids is community
based, and persistent symptoms are treated with outpatient
procedures such as rubber band ligation (RBL) for lower-
grade haemorrhoids, whereas surgical interventions are
often reserved for higher grade haemorrhoids or when
banding has been unsuccessful.
Given the prevalence of the condition, the management
of haemorrhoidal disease continues to have considerable
workload and cost implications for the UK national health
service (NHS), with approximately 38,000 haemorrhoidal
procedures being performed as hospital day-case or inpa-
tient admissions in England in 2014–2015 [3]. Over the last
two decades, understanding of the anatomy of
haemorrhoids has improved, leading to the introduction of
new surgical technologies into clinical practice. In 2009,
two main surgical treatments for haemorrhoids were
available: traditional (or excisional) surgical haemor-
rhoidectomy (TH) and stapled haemorrhoidopexy (SH). A
third treatment, haemorrhoidal artery ligation (HAL), had
been introduced but was not in widespread use.
TH involves excision of the haemorrhoidal cushions and
has generally been advocated for larger symptomatic
haemorrhoids (grades III and IV). SH was first developed
by Longo at the end of the last millennium [4]. In contrast
to the traditional approach, not all the haemorrhoidal tissue
is removed, instead the abnormally enlarged tissue is
removed, and the remaining tissue is repositioned back into
its normal anatomic position. This results in relocation of
the cushions and interruption of the feeding arteries. Its
potential advantages over traditional surgery included a
reduction of operating time, hospital stay, time to return to
work and postoperative pain [5]. These features, compared
with traditional haemorrhoid surgery, made it attractive to
patients and healthcare providers. Nevertheless, uncer-
tainties around complication rates, recurrence of symptoms
and costs preclude its widespread use across the NHS.
The economic evaluation addressed the question ‘‘what
is the relative cost effectiveness, assessed in terms of
incremental cost per quality-adjusted life-year (QALY),
and net benefits of SH and TH?’’. The cost-effectiveness
analysis followed the National Institute for Health and Care
Excellence (NICE) reference case [6] and the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) recommendations on conducting economic eval-
uations alongside clinical trials [7].
2 Methods
The economic evaluation was undertaken alongside a
multicentre randomised controlled trial comparing SH and
TH. This trial was registered with the ISRCTN registry
(number ISRCTN80061723). The study was approved by
the North of Scotland Research Ethics Committee on 18
June 2010 (reference number 10/20802/17). In brief, 777
participants (389 to receive SH and 388 to receive TH)
with grade II–IV haemorrhoids who had not previously
undergone SH or TH, were recruited from 32 UK hospitals
between January 2011 and August 2014 and followed-up
for 24 months. Sex, haemorrhoid grade and EQ-5D-3L
(EuroQol—5 dimensions—3 levels) baseline scores were
included as minimisation variables, thereby ensuring bal-
ance between the two treatment groups for these covariates.
Median age of the patients was 50 years, and 51% were
male. Over 60% of patients had grade III haemorrhoids,
and 35.8% of participants in the SH arm and 30.1% in the
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TH arm had received previous haemorrhoid treatment.
Details of the clinical results and study methodology are
available elsewhere [8]. The economic analysis was
undertaken from the perspective of the UK NHS, and costs
are expressed in pounds (£) for the financial year 2016 [8].
Costs and benefits incurred in the second year were dis-
counted at a rate of 3.5% per annum [6]. Details of the
methods used to derive resource use are described below.
2.1 Identification of Resources and Measurement
of Costs
We considered three broad areas of resource use: inter-
vention, secondary care and primary care. Use of the
intervention resource was recorded on a per patient basis.
The resources used to provide surgery were established by
consulting with relevant staff at participating centres (sur-
geons, theatre nurses, business managers) and members of
the study team to elicit information on consumables such as
the type of stapler used, frequency of use and other con-
sumables used during surgery, such as surgical trays, staff
mix of the surgical team (e.g. the grades of the operating
surgeon, anaesthetist and nurses and number of nurses).
The staplers were single use. In addition, operative details
and procedure duration were collected on the trial case
report forms (CRFs). CRF data were collected in the day
case clinic on the day of the operation and at 6 weeks.
CRFs were completed in clinic for those who attended the
review clinic and from patient notes for those who did not
attend.
Length-of-stay information was collected for each
participant through CRFs by recording the dates of
admission and discharge. For the initial intervention, cost
estimation focussed on those resources that differed
between the two interventions, i.e. we assumed there
would be no difference in time spent in recovery or time
on the ward following the procedure (for those managed
as day cases) as patient lists for day cases are planned
such that all patients are able to leave before the day-case
clinic closes. Information was collected for those who
were admitted. The use of subsequent care, such as
inpatient stay (duration of stay), reoperation or other
surgical interventions (such as SH, TH) and outpatient
visits over the study follow-up period, was obtained from
the CRFs (6 weeks) and patient questionnaire (12 and
24 months). The questionnaires used to collect subsequent
resource use data were developed by the trial team to
gather the relevant information. All primary care resource
use, such as general practice doctor and nurse contacts
and medications prescribed to treat haemorrhoids, was
obtained from the participant questionnaires administered
at 12 and 24 months. Self-reported subsequent resource
utilisation data was verified by contacting sites for all but
six cases (time constraints meant four cases were not
verified; in two cases, the sites did not respond to quer-
ies), and data were still included if the site did not con-
firm an intervention was carried out.
Costs of the health service utilisation were estimated by
combining the amount of resource used with unit costs of
this resource use. Unit costs were based on study-specific
estimates in combination with data from standard sources.
Unit costs for the consumables used in stapling were
obtained through personal communication with sites using
the consumables or from published price lists. Table 1
details the unit costs used, the source of the estimate and
any assumptions used to derive them.
Unit costs for outpatient visits were obtained from the
national reference costs [9]. Unit costs for general prac-
titioner visits were obtained from the Personal Social
Services Research Unit [10] unit costs of community care.
The unit costs of anaesthetic drugs such as propofol used
in the operation and post-surgery were derived from the
British National Formulary [11]. For each participant, the
number of visits were multiplied by the appropriate unit
cost. These costs were summed to produce a total cost per
patient. The unit cost of the type of stapler used in the
intervention was based on the cost of the stapler specified
for each patient.
2.2 Quality of Life
Effectiveness in the economic analysis was measured in
terms of QALYs. The EQ-5D-3L [12] generic quality-of-
life instrument was administered to all study participants at
baseline, 1 week, 3 weeks, 6 weeks, 12 months and
24 months, and UK index values were used. Quality-of-life
data were also collected using the 36-item MOS Short
Form health questionnaire (SF-36) [13] at baseline,
6 weeks, 12 months and 24 months. These data were
converted into a SF-6D utility index using a published
algorithm [14].
2.3 Missing Data
Missing data can lead to bias when undertaking economic
evaluation data analysis; this is especially true surrounding
resource use and quality-of-life data reported using par-
ticipant completed questionnaires. The amount of missing
EQ-5D-3L and resource use data varied over time. For
example, 210 (27%) patients were missing EQ-ED-3L data
at 12 months, 375 (48%) patients were missing QALY data
at 24 months, 345 (44%) patients were missing resource
use and therefore cost data at 12 months, and 421 (54%)
were missing total cost data at 24 months. The amount of
missing data was similar in both groups. One reason for
missing data could be that the data were collected at
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several time points; a patient may have returned baseline,
1-week, 3-week, 6-week, and 24-month questionnaires but
not the 12-month questionnaire. Briggs et al. [15] con-
cluded that imputing the missing data is preferable to a
complete or available case analysis.
2.4 Data Analysis
As the amount of data missing for some of the observations
was [5% (Ramsey et al. [7]), the primary economic
analysis was based on imputation of missing data and
Table 1 Unit costs for resources used in the within-trial economic analysis
Resource item Unit cost
(£)
Comments and source
Stapler
Ethicon PPH03 442.01 Box of 3, £1105 ex VAT (personal communication)
Chex CPH 32 276.00 Box of 3, £690 ex VAT (personal communication)
Covidien EEA DST 269.62 Box of 3, £674 ex VAT (personal communication)
Surgeon and anaesthetist
Consultant 2.30 Cost per minute at £138/h [10]
Specialty doctors (SAS) 2.13 Cost per minute at £128/h [10]
Surgical trainee 1.20 Cost per minute at £72/h [10]
Fellow 0.85 Cost per minute at £51/h [10]
Nurses
Band 5 0.72 Cost per minute at £43/h [10]
Band 6 0.85 Cost per minute at £51/h [10]
Anaesthetic drug cost
General 14.31 Various drugs (propofol) [11]
General and block 15.17 Various drugs (bupivacaine hydrochloride) [11]
Spinal 2.25 Various drugs (lidocaine) [11]
Interventions 6 weeks
Outpatient appointment 122.50 Average colorectal specialty [9]
Readmissions after interventiona 201.00 Admitted VB07Z emergency medicine, category 2 [9]
Emergency outpatient visitsb 162.00 Emergency medicine, category 2 investigation with category 2 treatment
[9]
Further interventions at 6 weeks, e.g.
haemorrhoidectomy
1106.00 Day case FZ22E intermediate anal procedures, C19 years, with CC score
0 [9]
Proctoscopy 10.99
Medicines, e.g. movical Various Based on patient report [11]
GTN paste 39.30 Price per 30 g tube [11]
Diltiazem cream 78.83 Price for 2% diltiazem cream per 30 g tube [11]
Repeat SH and TH further interventions
Day case 751.00 FZ23A minor anal procedures, C19 years [9]
Day case 1118.00 Day case FZ22D intermediate anal procedures, C19 years, with CC score
1–2 [9]
Post-discharge events
Doctor visits 44.00 Per 11.7-min consultation, including qualification costs [10]
Nurse visits 11.00 Per 15.5-min consultation, including qualification costs [10]
Medications
Analgesic Various As reported by participants [11]
Laxative Various As reported by participants [11]
Antibiotics Various As reported by participants [11]
Rubber ligation 181.00 FZ23A minor anal procedures, C19 years, procedures in outpatients [9]
CC complications, GTN glyceryl trinitrate, SAS specialty and associate specialistSH stapled haemorrhoidopexy, TH traditional haemor-
rhoidectomy, VAT value added tax
a Visits for post-operative complications, such as bleeding, that required hospitalisation
b Emergency visits for post-operative complications, such as pain, that did not result in admission
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included all participants as randomised, irrespective of the
treatment allocation. The imputation analysis was per-
formed using Stata’s multiple imputation (MI) procedure
[16]. Components of cost data were imputed based on
linear regression models adjusted for the minimisation
variables, which were centre, grade of haemorrhoidal dis-
ease (II, III or IV), baseline EQ-5D-3L score and sex.
Missing utility values were imputed using predictive mean
matching, accounting for the five closest estimates.
Chained equations were used for the imputations. The
imputation procedure predicted ten plausible alternative
imputed datasets, which was found to be sufficient to
provide stable estimates. Analysis of incremental costs and
outcomes was undertaken across the ten imputed datasets
and combined to generate one imputed estimate of incre-
mental costs and QALYs. Bootstrapping was conducted to
calculate confidence intervals for cost-effectiveness ratios.
The results of the differences in costs and QALYs were
plotted on cost-effectiveness acceptability curves
(CEACs). All data analyses were conducted using Stata
version 14TM software.
We used a generalised linear model (GLM) to explore
the skewness of data. The GLM allows for
heteroscedasticity by selecting an appropriate distribu-
tional family for the data [17]. The family offers alter-
native specifications to reflect the relationship between the
mean and the variance of the estimates under considera-
tion. The most appropriate distributional family was
selected by (1) performing a modified Parks test, which
identified two potentially viable distributional families for
costs, namely Gaussian or Gamma; and (2) consulting the
Akaike information criterion (AIC), which supported the
use of a Gaussian model with an identity link as having
the lowest AIC score (15.12) and the most appropriate
model fit. A standard ordinary least squares (OLS) model
was identified as the most appropriate and was applied to
the analysis of incremental QALY gains. All analyses
were conducted using robust standard errors. The primary
economic analysis presents estimates of the incremental
cost per QALY of SH versus TH. The incremental cost-
effectiveness ratio (ICER) can be compared against the
benchmark willingness-to-pay thresholds for cost effec-
tiveness in the NHS context of £20,000–30,000 per
QALY gained, as applied by NICE [18]. Analysis was
also undertaken using the number of recurrences of
haemorrhoids as an outcome.
2.5 Deterministic Sensitivity Analyses
The presentation of CEACs and scatter plots illustrates
some of the sampling uncertainty in the data; however,
other assumptions surrounding the most appropriate dis-
count rate and analysis models undertaken may create
additional uncertainty that is not captured in the presented
CEACs. Sensitivity analysis was applied to assess the
robustness of the results to realistic variations in the levels
of the underlying data and also alternative assumptions.
The analyses were conducted using QALYs derived from
the SF-36, complete case data and by varying the price of
staplers. The impact of using MI to impute missing data
was also explored by running a complete case analysis
(including only participants with complete cost and QALY
data). Sensitivity analysis was also undertaken to explore
the cost of staplers as the study was a pragmatic study and
the participating centres used the available staplers. Sub-
group analyses explored the possible treatment effect
modification of clinically important factors (haemorrhoidal
grade and sex) through the use of treatment by factor
interaction.
3 Results
3.1 Resource Use
On average, the use of intervention resources was similar
across both arms. The length of hospital stay (0.4 days)
was the same in each group. The number of further inter-
ventions was low over the 24-month period. For example,
at the 6-week time point, eight participants had undergone
TH: six in the SH and two in the TH arm. Three (SH) and
one (TH) participants had undergone SH, whereas four
(SH) and six (TH) had undergone RBL. Five (SH) and four
(TH) participants had received further treatment for skin
tags. Further non-surgical intervention resource use was
similar for both arms at 6 weeks post-treatment. However,
the number of participants receiving further interventions
was higher for SH at 12 months (SH 54 vs. TH 31) than at
24 months (SH 39 vs. TH 19).
Table 2 provides the details of average resource use
costs and cost differences between the two randomised
groups based on the available data. The estimates reported
in terms of NHS costs (Table 2) incurred after the partic-
ipants received the treatments show that the total mean cost
per patient was £922 ± standard deviation (SD) 587 in the
SH arm and £621 ± 582.98 in the TH arm. There was a
statistically significant difference in the (adjusted) total
mean costs (£323; 95% confidence interval [CI] 237–409)
of the interventions.
Low resource use means that total cost data were highly
skewed to the right because most of the participants had
low costs or no cost at all, but a few had high costs.
Although costs of resource use measured during the
intervention, such as staff time, anaesthetic used and
admissions, were similar in both arms, the mean cost of
interventions was £273 higher in SH (95% CI 240–306)
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because of the additional costs of the staplers (Table 2).
The costs reported at the 6-week visit were £25 lower in
SH (95% CI -68 to 17) but not statistically significant. The
other patient-reported costs between 6 weeks and
12 months were higher for SH £33 (95% CI -2 to 68) but
not statistically significant, and the total 12-month costs
were significantly higher for the SH arm £309 (95% CI
238–380) than for the TH arm. The 12- to 24-month costs
were significantly higher for the SH arm £48 (95% CI
13–82) because it had more admissions and outpatient
visits. Total mean costs over the 24-month follow-up per-
iod were significantly higher for the SH arm (£323; 95% CI
237–410) than for the TH arm. The incremental differences
are based on regression models (GLM [costs] and OLS
[QALYs]), with adjustments for baseline covariates,
including baseline EQ-SD-3L score.
3.2 Quality-Adjusted Life-Years
The EQ-5D-3L scores for study intervention at baseline,
1 week, 3 weeks, 6 weeks, 12 months and 24 months are
shown in Table 3. They were higher for SH at 1 week and
3 weeks but lower at 6 weeks, 12 months and 24 months.
From these data, we estimated the mean QALYs over the
2 years as 1.676 ± SD 0.384 for the SH arm and
1.738 ± SD 0.334 for the TH arm.
The mean difference in EQ-SD-3L scores after adjusting
for minimisation variables and baseline EQ-5D-3L scores
was statistically significantly higher for SH at 1 week
(0.135; 95% CI 0.082–0.188) and 3 weeks (0.05; 95% CI
0.008–0.091) but was significantly lower at 12 months (-
0.064; 95% CI -0.095 to -0.033) and 24 months (-0.046;
95% CI -0.079 to -0.013). The QALY difference was -
Table 2 Mean UK national
health service costs (£) and
adjusted mean difference for
study interventions
Resource SH TH Mean difference (95% CI)a
Intervention
Time of staff at operation 208 ± 82 (349) 213 ± 88 (360) -5 (-18 to 9)
Anaesthetic used 14 ± 3 (356) 14 ± 2 (361) -0.19 (-0.53 to 0.15)
Stapler 307 ± 154 (346) 32 ± 111 (362) 275 (207 to 342)
Admissions during intervention 51 ± 134 (354) 49 ± 145 (362) 3 (-22 to 27)
Total intervention cost 581 ± 230 (341) 308 ± 215 (360) 273 (240 to 306)
6-week visit 151 ± 314 (305) 175 ± 390 (304) -25 (-68 to 17)
Total 12 months 869 ± 579 (197) 547 ± 447 (188) 309 (237 to 380)
Total 12–24 monthsb 102 ± 366 (244) 56 ± 219 (233) 48 (13 to 82)
Total over 24 months 922 ± 587 (158) 621 ± 583 (156) 323 (237 to 410)
Data are presented as mean ± standard deviation (N)
CI confidence interval, EQ-5D-3L EuroQoL—five dimensions—three levels instrument, N number of
patients included in the analysis, SD standard deviation, SH stapled haemorrhoidopexy, TH traditional
haemorrhoidectomy
a Cost difference adjusted for minimisation covariates and baseline EQ-5D-3L
b 24-month costs discounted at 3.5%. Positive cost difference values indicate that SH costs more than TH
and vice versa
Table 3 Quality of life (EQ-5D
and quality-adjusted life-year)
by study intervention
Time SH TH Mean difference (SH–TH)a
Baseline 0.762 ± 0.247 (388) 0.764 ± 0.264 (386)
1 week 0.592 ± 0.315 (298) 0.458 ± 0.337 (291) 0.135 (0.082 to 0.188)
3 weeks 0.802 ± 0.244 (285) 0.750 ± 0.244 (276) 0.050 (0.008 to 0.091)
6 weeks 0.846 ± 0.220 (305) 0.851 ± 0.235 (303) -0.004 (-0.037 to 0.029)
12 months 0.822 ± 0.252 (291) 0.880 ± 0.209 (274) -0.064 (-0.095 to -0.033)
24 monthsb 0.802 ± 0.242 (283) 0.841 ± 0.192 (272) -0.046 (-0.079 to -0.013)
QALYc 1.676 ± 0.384 (206) 1.738 ± 0.334 (194) -0.071 (-0.127 to -0.016)
Data are presented as mean ± standard deviation (N) or mean difference (95% confidence interval)
EQ-5D EuroQoL—five dimensions instrument, N number of patients included in the analysis, QALY
quality-adjusted life-year, SH stapled haemorrhoidopexy, TH traditional haemorrhoidectomy
a A positive sign means SH has a higher score than TH; a negative value means SH has a lower score
b 24-month EQ-5D-3L score discounted at 3.5% per annum
c QALYs gained are based on an area under a curve, and the EQ-SD-3L scores are point estimates at
specific times
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0.071 (95% CI -0.127 to -0.016)—statistically signifi-
cantly lower for SH than for TH.
3.3 Cost-Utility Results
As mentioned, the base-case analysis was based on multi-
ple imputed data. The estimated costs and QALYs are
reported in Table 4. Total costs were higher for the SH
group: mean difference £337 (95% CI 251–423). Total
QALYs were lower in the SH group: mean difference -
0.074 (95% CI -0.070 to -0.011). Both these differences
were statistically significant.
The CEAC generated from the base-case cost-effec-
tiveness analysis (Fig. 1) shows there is zero probability of
SH being cost effective at either the £20,000 or the £30,000
willingness-to-pay threshold. The scatter plot graph
(Fig. 2) shows the point estimate and the distribution of the
joint differences in costs and effects. The ICER point
estimate and almost all of the bootstrapped estimates fall in
the north-west quadrant of the cost-effectiveness plane,
suggesting SH is significantly more costly and less effec-
tive than TH.
The results of cost-effectiveness analysis based on the
number of recurrences averted were similar to those of the
base case (Table 3). On average, significantly more
recurrences occurred in the SH arm (0.18; 95% CI
0.245–0.120), and SH was more costly than TH; therefore,
SH was dominated by TH.
3.4 Sensitivity Analysis
The results of the analysis considering the complete cases
(based on participants with both cost and QALY data) are
presented in Table 4. On average, SH cost £288 (95% CI
190–386) more than TH and had -0.060 (95% CI -0.113
to -0.007) fewer QALYs than TH. The results of the
complete cases were broadly similar to those of the base-
case analysis. On average, SH had higher costs and lower
QALYs than TH. The chance that SH might be considered
to be cost effective at the £30,000 threshold was 1.7%.
Table 4 Estimation of cost-utility analysis
Arm Costs Difference QALY Difference ICERa
Baseline imputed data
SH (N = 389) 941 ± 415 1.62 ± 0.43 Dominated
TH (N = 386) 602 ± 507 337 [41] (251–423) 1.69 ± 0.38 -0.070 [0.027] (0.127 to -0.011)
Number of recurrences
SH (N = 389) 941 ± 415 0.327 ± 0.008 Dominated
TH (N = 386) 602 ± 507 337 [41] (251–423) 0.142 ± 0.006 0.18 [0.030] (0.245–0.120)
Complete case data
SH (N = 148) 864 ± 415 1.72 ± 0.33 Dominated
TH (N = 149) 573 ± 507 288 [473] (190–386) 1.77 ± 0.30 -0.060 [0.026]
Using SF-6D data
SH (N = 126) 873 ± 510 1.54 ± 0.23 Dominated
TH (N = 130) 549 ± 493 313 (204–423) 1.61 ± 0.20 -0.063 (-0.107 to -0.018)
Varying the cost of staplers
Cost Mean difference (SH–TH) SE p value 95% CI ICER
269b 216 45 0.000 124 to 309 SH dominated
150 119 43 0.010 31 to 206 SH dominated
125 98 42 0.029 11 to 185 SH dominated
100 78 42 0.076 -9 to 164 -1109
75 57 42 0.182 -29 to 143 -817
50 37 41 0.384 -49 to 122 -525
45 33 41 0.438 -53 to 118 -466
0 -4 41 0.919 -89 to 81 60
Costs are presented in £. Data are presented as mean ± standard deviation or difference [standard error] (95% confidence interval)
CI confidence interval, ICER incremental cost-effectiveness ratio, N number of patients included in the analysis, QALY quality-adjusted life-year,
SE standard error, SF-6D MOS 36-item Short-Form Health Survey, SH stapled haemorrhoidopexy, TH traditional haemorrhoidectomy
a SH dominated means that SH costs more and has fewer QALYs than TH
b The lowest price of staplers used in the study
Cost Effectiveness of SH vs. TH for Treatment of Haemorrhoids 277
The utility and QALY scores derived from the SF-36
followed a similar pattern to those of the EQ-SD-3L. On
average, the 6-week SH utility score was -0.015 lower
than that of TH, but this did not meet statistical signifi-
cance. However, it was lower at 12 months (-0.040) and at
24 months (-0.034), and these differences were statisti-
cally significant (p\ 0.05). The QALYs were -0.04 (95%
CI -0.069 to -0.013) lower for SH than for TH. There is
only a 0.1% chance of SH being considered cost effective
at willingness-to-pay thresholds of £20,000 or £30,000
(based on QALYs derived from the SF-6D).
Further analysis was undertaken varying the cost of the
staplers and using the least expensive of those used in the
study (Table 4). The QALY difference remained the same
(-0.070 [0.027]; 95% CI -0.127 to -0.011). The results
based on using the least expensive stapler were similar to
those of the base-case analysis. For costs of £125 or above,
SH cost significantly more and had lower QALYs than TH.
SH remained marginally more costly than TH unless the
cost of the stapler fell to zero. The results of the analysis
that assumed no additional cost from staplers suggested SH
had a 0.1% chance of being considered cost effective at
both the £20,000 and the £30,000 threshold. Results of the
analysis incorporating subgroup interaction terms relating
to the sex and grade of haemorrhoidal disease were not
statistically significant.
4 Discussion
The results of the base-case analysis suggested that, on
average, SH cost £337 (95% CI 251–423) more and had -
0.07 (95% CI -0.13 to -0.01) fewer QALYs than TH. The
cost-utility analysis suggested there was no chance of SH
being considered cost effective at £20,000 or £30,000
willingness-to-pay thresholds. These results are robust;
none of the sensitivity analyses altered the conclusions that
SH always cost more and generated fewer QALYs than
TH.
The QALYs derived from the two different instruments
(EQ-5D-3L and SF-6D) were similar. The benefits of short-
term post-operative pain experienced by patients in the SH
arm was reflected in the EQ-5D-3L utility scores at 1 and
3 weeks (statistically significantly higher) and at 6 weeks
(not significantly higher), but any gains in quality of life
were offset by the higher rate of recurrence at 12 and
24 months. Although the SF-6D results were lower for the
SH arm at 6 weeks, the results were not significant. The
12- and 24-month SF-6D utility scores were similar to
those of the EQ-5D-3L.
The major driver for the increased cost of SH was the
cost of staplers, but sensitivity analysis conducted varying
the cost of staplers indicated the cost-effectiveness con-
clusions were not particularly sensitive to this parameter
because of the superior QALY estimates for TH. The study
was a pragmatic study, and research sites were allowed to
use their choice of stapler type. The stapler cost analyses
suggested the cost of the stapler would have to fall to zero
for cost differences to become positive for SH, and even in
this instance the costs would not be statistically signifi-
cantly different. The distribution of the estimates of costs
and QALY differences would lie in the south-west quad-
rant of the cost-effectiveness plane (SH would cost less but
have lower QALYs than TH), where cost savings do not
outweigh associated QALY losses.
A key strength of this study was that it was an economic
evaluation undertaken alongside a large randomised con-
trolled trial to compare SH and TH. It was a multicentre
study with centres across the UK that followed-up partic-
ipants for 24 months. This suggests the results could be
generalisable to all patient populations seeking treatment
for grade II–IV haemorrhoids. The number of patients
recruited ensured considerable confidence in the conclu-
sions drawn from the trial-based cost-effectiveness
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analyses. The existing economic evaluations of these
treatments undertaken alongside a randomised controlled
trial include low numbers of participants and shorter fol-
low-up times [19, 20]. The other economic evaluations
[21, 22] were conducted within a modelling framework and
used data from small studies.
This study also captured the effect of these treatments
on patient quality of life, using the EQ-5D-3L to mea-
sure the effect of pain or complications on quality of life
post-surgery over several time points, particularly early
time points (1, 3 and 6 weeks) where they were antici-
pated to affect quality of life. Short-term quality-of-life
scores were better for SH, reflecting lower rates of pain
in the immediate post-operative period; however, the
longer-term scores were better for TH, which had fewer
residual haemorrhoidal symptoms, recurrences and re-
interventions. The quality-of-life estimates based on the
additional instrument, SF-6D, were similar in direction
and magnitude to those based on the EQ-5D-3L
instrument.
One of the limitations of the economic analysis was the
amount of missing data. This could be because the popu-
lation was based on working age patients and haemorrhoids
are a chronic condition that may be considered by some to
be a sensitive condition. However, the amount of missing
data was similar in both arms. The MI method, which
assumed the data to be missing at random, was conducted
to address this challenge, and the results of the analyses
from the imputed dataset and complete case were similar.
The conclusion that, on average, SH cost more and had
fewer QALYs than TH remained the same, irrespective of
the approach used.
The results of the economic analysis are inconsistent
with those published in Burch et al. [21], who reported that
TH and SH had similar costs because the staple gun costs
in the SH arm were offset by hospital stay savings in the
TH arm. Our results suggest that the operation and time
spent in hospital were similar in SH and TH, so there were
no cost savings in inpatient stay. The cost differences in
our results were driven by the additional cost of stapler
guns. Burch et al. [21] reported that the QALYs were
similar in both arms. Ho et al. [19] reported that the total
costs incurred for TH at 1 year were less (£9210.17 [16.85]
vs. 1283.09 [31.59]; p\ 0.005). Thaha et al. [20] reported
that the extra mean cost (£312.51) incurred for SH was due
to additional costs for the stapler. Ribarac et al. [22]
reported that an incremental cost of £33 was incurred for
SH after 1 year. These cost results were similar to ours, as
they indicated that SH cost more than TH.
The results of our study indicated that, for SH, the
quality-of-life gains experienced post-surgery were less
than the quality-of-life reductions in the 24-month follow-
up period. Burch et al. [21] reported no difference in the
quality-of-life measures for the two treatments. The qual-
ity-of-life results in our study were similar to those of
Ribaric´ et al. [22], Ho et al. [19] and Thaha et al. [20], who
all reported that SH was less effective than TH. However,
all of the studies indicated a higher rate of prolapse and re-
intervention for prolapse in the SH group, which was
reflected in the higher follow-up costs and lower QALYs
experienced in the SH group in our study.
5 Conclusions
The analysis suggested that SH cost more and was less
effective than TH. These results were supported by the
sensitivity analyses and the fact that secondary clinical
outcomes such as tenesmus were more prevalent in the SH
arm (p\ 0.001) and more participants reported recurrence
of haemorrhoids at both 12 and 24 months. Therefore, TH
is a superior surgical treatment for the management of
grades II–IV haemorrhoids when compared with SH in
terms of both clinical and cost effectiveness. Robust eco-
nomic data on haemorrhoid surgery are scarce; however, if
the results of this study are adopted into practice, sub-
stantial annual cost savings in publicly funded health ser-
vices could be achieved. Given the current financial status
of the NHS, commissioners of healthcare may consider
being more prescriptive about procedures being offered for
surgical treatment of haemorrhoids.
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